O	0	6	Effect
O	7	9	of
O	10	13	the
B-intervention	14	26	gonadotropin
I-intervention	26	27	-
I-intervention	27	36	releasing
I-intervention	37	44	hormone
I-intervention	45	53	analogue
I-intervention	54	65	triptorelin
O	66	68	on
O	69	72	the
O	73	83	occurrence
O	84	86	of
B-condition	87	99	chemotherapy
I-condition	99	100	-
I-condition	100	107	induced
I-condition	108	113	early
I-condition	114	123	menopause
O	124	126	in
O	127	140	premenopausal
O	141	146	women
O	147	151	with
O	152	158	breast
O	159	165	cancer
O	165	166	:
O	167	168	a
O	169	179	randomized
O	180	185	trial
O	185	186	.

O	187	200	Premenopausal
O	201	209	patients
O	210	214	with
O	215	221	breast
O	222	228	cancer
O	229	232	are
O	233	235	at
O	236	240	high
O	241	245	risk
O	246	248	of
O	249	258	premature
O	259	266	ovarian
O	267	274	failure
O	275	282	induced
O	283	285	by
O	286	294	systemic
O	295	305	treatments
O	305	306	,
O	307	310	but
O	311	313	no
O	314	322	standard
O	323	333	strategies
O	334	337	for
O	338	348	preventing
O	349	353	this
O	354	361	adverse
O	362	368	effect
O	369	372	are
O	373	376	yet
O	377	386	available
O	386	387	.

O	388	390	To
O	391	400	determine
O	401	404	the
O	405	411	effect
O	412	414	of
O	415	418	the
O	419	428	temporary
O	429	436	ovarian
O	437	448	suppression
O	449	457	obtained
O	458	460	by
O	461	474	administering
O	475	478	the
O	479	491	gonadotropin
O	491	492	-
O	492	501	releasing
O	502	509	hormone
O	510	518	analogue
O	519	530	triptorelin
O	531	537	during
O	538	550	chemotherapy
O	551	553	on
O	554	557	the
O	558	567	incidence
O	568	570	of
O	571	576	early
O	577	586	menopause
O	587	589	in
B-eligibility	590	595	young
I-eligibility	596	604	patients
I-eligibility	605	609	with
I-eligibility	610	616	breast
I-eligibility	617	623	cancer
I-eligibility	624	634	undergoing
I-eligibility	635	643	adjuvant
I-eligibility	644	646	or
I-eligibility	647	658	neoadjuvant
I-eligibility	659	671	chemotherapy
O	671	672	.

O	673	676	The
O	677	684	PROMISE
O	684	685	-
O	685	689	GIM6
O	690	691	(
O	691	701	Prevention
O	702	704	of
O	705	714	Menopause
O	715	722	Induced
O	723	725	by
O	726	738	Chemotherapy
O	738	739	:
O	740	741	A
O	742	747	Study
O	748	750	in
O	751	756	Early
O	757	763	Breast
O	764	770	Cancer
O	771	779	Patients
O	779	780	-
O	780	786	Gruppo
O	787	795	Italiano
O	796	804	Mammella
O	805	806	6
O	806	807	)
O	808	813	study
O	813	814	,
O	815	816	a
O	817	825	parallel
O	825	826	,
O	827	837	randomized
O	837	838	,
O	839	843	open
O	843	844	-
O	844	849	label
O	849	850	,
O	851	856	phase
O	857	858	3
O	859	870	superiority
O	871	876	trial
O	876	877	,
O	878	881	was
O	882	891	conducted
O	892	894	at
O	895	897	16
O	898	903	sites
O	904	906	in
B-location	907	912	Italy
O	913	916	and
O	917	925	enrolled
B-total-participants	926	929	281
O	930	938	patients
O	939	946	between
O	947	954	October
O	955	959	2003
O	960	963	and
O	964	971	January
O	972	976	2008
O	976	977	.

O	978	981	The
O	982	990	patients
O	991	995	were
B-eligibility	996	1009	premenopausal
I-eligibility	1010	1015	women
I-eligibility	1016	1020	with
I-eligibility	1021	1026	stage
I-eligibility	1027	1028	I
I-eligibility	1029	1036	through
I-eligibility	1037	1040	III
I-eligibility	1041	1047	breast
I-eligibility	1048	1054	cancer
I-eligibility	1055	1058	who
I-eligibility	1059	1063	were
I-eligibility	1064	1074	candidates
I-eligibility	1075	1078	for
I-eligibility	1079	1087	adjuvant
I-eligibility	1088	1090	or
I-eligibility	1091	1102	neoadjuvant
I-eligibility	1103	1115	chemotherapy
O	1115	1116	.

O	1117	1125	Assuming
O	1126	1127	a
O	1128	1130	60
O	1130	1131	%
O	1132	1136	rate
O	1137	1139	of
O	1140	1145	early
O	1146	1155	menopause
O	1156	1158	in
O	1159	1162	the
O	1163	1168	group
O	1169	1176	treated
O	1177	1181	with
B-control	1182	1194	chemotherapy
I-control	1195	1200	alone
O	1200	1201	,
O	1202	1204	it
O	1205	1208	was
O	1209	1218	estimated
O	1219	1223	that
O	1224	1227	280
O	1228	1236	patients
O	1237	1240	had
O	1241	1243	to
O	1244	1246	be
O	1247	1255	enrolled
O	1256	1258	to
O	1259	1265	detect
O	1266	1267	a
O	1268	1270	20
O	1270	1271	%
O	1272	1280	absolute
O	1281	1290	reduction
O	1291	1293	in
O	1294	1299	early
O	1300	1309	menopause
O	1310	1312	in
O	1313	1316	the
O	1317	1322	group
O	1323	1330	treated
O	1331	1335	with
O	1336	1348	chemotherapy
O	1349	1353	plus
O	1354	1365	triptorelin
O	1365	1366	.

O	1367	1370	The
O	1371	1380	intention
O	1380	1381	-
O	1381	1383	to
O	1383	1384	-
O	1384	1389	treat
O	1390	1398	analysis
O	1399	1402	was
O	1403	1412	performed
O	1413	1415	by
O	1416	1425	including
O	1426	1429	all
O	1430	1440	randomized
O	1441	1449	patients
O	1450	1453	and
O	1454	1459	using
O	1460	1467	imputed
O	1468	1474	values
O	1475	1478	for
O	1479	1486	missing
O	1487	1491	data
O	1491	1492	.

O	1493	1499	Before
O	1500	1509	beginning
O	1510	1522	chemotherapy
O	1522	1523	,
O	1524	1532	patients
O	1533	1537	were
O	1538	1546	randomly
O	1547	1556	allocated
O	1557	1559	to
O	1560	1567	receive
O	1568	1580	chemotherapy
O	1581	1586	alone
O	1587	1589	or
O	1590	1598	combined
O	1599	1603	with
O	1604	1615	triptorelin
O	1615	1616	.

O	1617	1628	Triptorelin
O	1629	1632	was
O	1633	1645	administered
O	1646	1661	intramuscularly
O	1662	1664	at
O	1665	1666	a
O	1667	1671	dose
O	1672	1674	of
O	1675	1676	3
O	1676	1677	.
O	1677	1679	75
O	1680	1682	mg
O	1683	1685	at
O	1686	1691	least
O	1692	1693	1
O	1694	1698	week
O	1699	1705	before
O	1706	1709	the
O	1710	1715	start
O	1716	1718	of
O	1719	1731	chemotherapy
O	1732	1735	and
O	1736	1740	then
O	1741	1746	every
O	1747	1748	4
O	1749	1754	weeks
O	1755	1758	for
O	1759	1762	the
O	1763	1771	duration
O	1772	1774	of
O	1775	1787	chemotherapy
O	1787	1788	.

O	1789	1798	Incidence
O	1799	1801	of
O	1802	1807	early
O	1808	1817	menopause
O	1818	1819	(
O	1819	1826	defined
O	1827	1829	as
O	1830	1832	no
O	1833	1843	resumption
O	1844	1846	of
O	1847	1856	menstrual
O	1857	1865	activity
O	1866	1869	and
O	1870	1884	postmenopausal
O	1885	1891	levels
O	1892	1894	of
O	1895	1903	follicle
O	1903	1904	-
O	1904	1915	stimulating
O	1916	1923	hormone
O	1924	1927	and
O	1928	1937	estradiol
O	1938	1939	1
O	1940	1944	year
O	1945	1950	after
O	1951	1954	the
O	1955	1959	last
O	1960	1965	cycle
O	1966	1968	of
O	1969	1981	chemotherapy
O	1981	1982	)
O	1982	1983	.

O	1984	1987	The
O	1988	1996	clinical
O	1997	2000	and
O	2001	2006	tumor
O	2007	2022	characteristics
O	2023	2025	of
O	2026	2029	the
B-control-participants	2030	2033	133
O	2034	2042	patients
O	2043	2053	randomized
O	2054	2056	to
O	2057	2069	chemotherapy
O	2070	2075	alone
O	2076	2079	and
O	2080	2083	the
B-intervention-participants	2084	2087	148
O	2088	2096	patients
O	2097	2107	randomized
O	2108	2110	to
O	2111	2123	chemotherapy
O	2124	2128	plus
O	2129	2140	triptorelin
O	2141	2145	were
O	2146	2153	similar
O	2153	2154	.

O	2155	2161	Twelve
O	2162	2168	months
O	2169	2174	after
O	2175	2178	the
O	2179	2183	last
O	2184	2189	cycle
O	2190	2192	of
O	2193	2205	chemotherapy
O	2206	2207	(
O	2207	2211	last
O	2212	2218	follow
O	2218	2219	-
O	2219	2221	up
O	2221	2222	,
O	2223	2229	August
O	2230	2232	18
O	2232	2233	,
O	2234	2238	2009
O	2238	2239	)
O	2239	2240	,
O	2241	2244	the
B-outcome	2245	2249	rate
I-outcome	2250	2252	of
I-outcome	2253	2258	early
I-outcome	2259	2268	menopause
O	2269	2272	was
B-cv-bin-percent	2273	2275	25
I-cv-bin-percent	2275	2276	.
I-cv-bin-percent	2276	2277	9
I-cv-bin-percent	2277	2278	%
O	2279	2281	in
O	2282	2285	the
O	2286	2298	chemotherapy
O	2298	2299	-
O	2299	2304	alone
O	2305	2310	group
O	2311	2314	and
B-iv-bin-percent	2315	2316	8
I-iv-bin-percent	2316	2317	.
I-iv-bin-percent	2317	2318	9
I-iv-bin-percent	2318	2319	%
O	2320	2322	in
O	2323	2326	the
O	2327	2339	chemotherapy
O	2340	2344	plus
O	2345	2356	triptorelin
O	2357	2362	group
O	2362	2363	,
O	2364	2366	an
O	2367	2375	absolute
O	2376	2386	difference
O	2387	2389	of
O	2390	2391	-
O	2391	2393	17
O	2393	2394	%
O	2395	2396	(
O	2396	2398	95
O	2398	2399	%
O	2400	2410	confidence
O	2411	2419	interval
O	2419	2420	,
O	2421	2422	-
O	2422	2424	26
O	2424	2425	%
O	2426	2428	to
O	2429	2430	-
O	2430	2431	7
O	2431	2432	.
O	2432	2433	9
O	2433	2434	%
O	2434	2435	;
O	2436	2437	P
O	2438	2439	<
O	2440	2441	.
O	2441	2444	001
O	2444	2445	)
O	2445	2446	.

O	2447	2450	The
O	2451	2455	odds
O	2456	2461	ratio
O	2462	2465	for
B-outcome	2466	2475	treatment
I-outcome	2475	2476	-
I-outcome	2476	2483	related
I-outcome	2484	2489	early
I-outcome	2490	2499	menopause
O	2500	2503	was
O	2504	2505	0
O	2505	2506	.
O	2506	2508	28
O	2509	2510	(
O	2510	2512	95
O	2512	2513	%
O	2514	2524	confidence
O	2525	2533	interval
O	2533	2534	,
O	2535	2536	0
O	2536	2537	.
O	2537	2539	14
O	2540	2542	to
O	2543	2544	0
O	2544	2545	.
O	2545	2547	59
O	2547	2548	;
O	2549	2550	P
O	2551	2552	<
O	2553	2554	.
O	2554	2557	001
O	2557	2558	)
O	2558	2559	.

O	2560	2563	The
O	2564	2567	use
O	2568	2570	of
O	2571	2582	triptorelin
O	2582	2583	-
O	2583	2590	induced
O	2591	2600	temporary
O	2601	2608	ovarian
O	2609	2620	suppression
O	2621	2627	during
O	2628	2640	chemotherapy
O	2641	2643	in
O	2644	2657	premenopausal
O	2658	2666	patients
O	2667	2671	with
O	2672	2677	early
O	2677	2678	-
O	2678	2683	stage
O	2684	2690	breast
O	2691	2697	cancer
O	2698	2705	reduced
O	2706	2709	the
O	2710	2720	occurrence
O	2721	2723	of
O	2724	2736	chemotherapy
O	2736	2737	-
O	2737	2744	induced
O	2745	2750	early
O	2751	2760	menopause
O	2760	2761	.
O	2762	2776	clinicaltrials
O	2776	2777	.
O	2777	2780	gov
O	2781	2791	Identifier
O	2791	2792	:
O	2793	2804	NCT00311636
O	2804	2805	.
